住院治疗是否能改善心房动患者口服抗凝剂的优化?
Belayneh Kefale1,2, Gregory M Peterson1, Corinne Mirkazemi1
1School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.
European journal of clinical investigation
|February 14, 2025
概括
住院治疗改善了心房患者口服抗凝剂 (OAC) 的使用情况,但近一半不适当的OAC处方仍未得到纠正. 需要进一步的干预来优化在住院期间的OAC治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 住院治疗为药物审查和优化提供了一个关键的机会.
- 在心房患者中,口服抗凝剂 (OAC) 的使用对于预防中风至关重要.
- 在住院期间的药物适当性仍然被低估.
研究的目的:
- 评估OAC治疗在AF患者在入院和出院时的适当性.
- 确定住院治疗是否会改善AF患者的OAC治疗.
- 确定影响纠正不适当的OAC治疗的因素.
主要方法:
- 在澳大利亚皇家霍巴特医院进行了一项观察性研究.
- 在入院和出院时,根据澳大利亚的指导方针评估了OAC治疗的适当性.
- 多重后勤回归确定了与纠正不适当的OAC治疗相关的因素.
主要成果:
- 近一半 (47.1%) 的AF患者在入院时接受了不适当的OAC治疗.
- OAC治疗的适当性从入院时的53.8%显著提高到出院时的73.8% (p < .001).
- 在接受中风或心脏病科病房的患者和患有出血的患者中,不适当的OAC治疗更有可能得到纠正.
结论:
- 住院治疗显著改善了AF患者OAC治疗的适当性.
- 然而,51.0%的入院时OAC治疗不适当的患者在住院期间没有得到纠正.
- 加强医院护理团队纠正不适当的OAC治疗的干预措施是有必要的.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
597
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
597
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
40
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
40
Heart Failure Drugs: Diuretics
334
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
Dosage Regimen: Fixed Dose
1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457


